Merck & Co. (MRK): Bridging the Keytruda Cliff with ADC Innovation and Winrevair Momentum | 2026 Strategic Outlook

from AI Corporate Analysis Deep Dive · host aideepdiveofficial

we evaluate the strategic pivot of pharmaceutical giant Merck as it prepares for the 2028 patent cliff of its blockbuster oncology drug, Keytruda. Despite a subdued 2026 financial guidance, Merck is executing a multi-pronged diversification strategy, leveraging next-generation ADC (Antibody-Drug Conjugates) and a booming cardiometabolic franchise.

What this episode covers

NOW PLAYING

0:00 14:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AI Corporate Analysis Deep Dive?

This episode is 14 minutes long.

When was this AI Corporate Analysis Deep Dive episode published?

This episode was published on February 16, 2026.

What is this episode about?

Can I download this AI Corporate Analysis Deep Dive episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!